SEC Filing Summary for BeOne Medicines Ltd.

On June 16, 2026, Lai Wang, President, Global Head of R&D at BeOne Medicines Ltd., reported a disposition of 1,169 American Depositary Shares. The shares were sold at a weighted average price of $265.3857, with individual sales ranging from $265.385 to $265.775. This transaction was part of a mandatory tax withholding due to the vesting of a restricted share unit award. Following this transaction, Lai Wang directly holds 1,694,888 ordinary shares. Additionally, he indirectly holds 601,965 ordinary shares through a limited liability company, and has an indirect economic interest in an indeterminable portion of RMB Shares held by an employee participation plan, though he disclaims beneficial ownership and voting/dispositive power over those shares. The RMB Shares were acquired by the employee plan directly from the issuer in the STAR Offering.